Bill

Bill > HR9297


US HR9297

US HR9297
Pre-Approval Information Exchange Act of 2022


summary

Introduced
11/15/2022
In Committee
11/16/2022
Crossed Over
Passed
Dead
01/03/2023

Introduced Session

117th Congress

Bill Summary

A BILL To amend the Federal Food, Drug, and Cosmetic Act to facilitate the exchange of certain product information, and for other purposes.

AI Summary

This bill, the Pre-Approval Information Exchange Act of 2022, amends the Federal Food, Drug, and Cosmetic Act to facilitate the exchange of certain product information between drug and device manufacturers and payors, formulary committees, or other similar entities. It allows for the sharing of information about investigational drugs or devices that have not yet been approved, cleared, or licensed by the FDA, as long as certain requirements are met, such as including clear disclaimers and avoiding claims about safety or efficacy. The bill also requires the Government Accountability Office to conduct a study on the provision and use of this information after 5 years and 6 months of enactment.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (6)

Last Action

Referred to the Subcommittee on Health. (on 11/16/2022)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...